MBS now meets customers’ broad norovirus diagnostic goals.
Portland, Maine (PRWEB) November 12, 2014
MBS has added a new norovirus antibody to a diagnostic panel that now includes seven monoclonal antibodies. MAB242P, the most recently developed antibody, is the first MBS antibody to recognize both GI and GII strains of norovirus. MAB242P complements our previous offering of antibodies that were exclusive for either GI or GII strains of the virus. With this complete panel, MBS now meets customers’ broad and diverse diagnostic goals.
Norovirus is the most common cause of acute gastroenteritis in the United States. Each year, it causes 19-21 million illnesses and contributes to 56,000-71,000 hospitalizations and 570-800 deaths. Norovirus is also the most common cause of foodborne-disease outbreaks in the United States. There are currently five known genogroups, of which three cause human disease: GI, GII and GIV. According to the CDC, since 2002, GII.4 has been the most common cause of Norovirus outbreaks.
Maine Biotechnology Services is a premier provider of antibody products and services, from design and development to production and characterization. MBS extends the creativity and experience necessary for the most complex hybridoma development projects. A wide variety of tools are utilized by MBS to allow customers the opportunity to refine clone selection early in a project, and to support prototype assay validation.